Supplier: BGI Genomics
Contact person: Mr. Tommy Ru
Position:
Address: beijing
Country: China
Phone: - Mobi: 17722567742
BGI Genomics Program Seeks to Validate Signatera Test for Co
Price:
NEW YORK – Building on an earlier licensing partnership, BGI Genomics and Natera have launched a clinical research program to use Signatera in China for colorectal cancer patients.
The BGI China multicenter program, which launched last week, is the first clinical research application of Natera's Signatera tumor-informed residual disease test in China for use with colorectal cancer patients.
Recent data published in Clinical Cancer Research showed that Signatera can be used to stratify colorectal cancer patients based on growth or stability of their circulating tumor DNA levels over time, and the firm has previously validated the approach for early detection and prediction of impending cancer recurrence.
In 2020, the test also received Medicare coverage in the US for patients with stage II to stage III colon cancer.
Natera and BGI Genomics' partnership began when BGI saw the minimal residual disease test had been validated in the US and thought it would be beneficial to bring the technology to China for clinical practice, Shida Zhu, general manager of BGI Oncology, said. In June of this year, Signatera first became available to biopharmaceutical customers and clinicians in China under the brand name Hua Jian Wei.
Zhu said the firm waited to begin the clinical program until BGI had local production and delivery facilities available in China to perform the testing. It took two years to finish the facilities, he added, and Natera provided samples from its US-based production facilities to ensure the Chinese facilities were producing comparable results. Natera declined to comment on the partnership.
The BGI China multicenter program, which launched last week, is the first clinical research application of Natera's Signatera tumor-informed residual disease test in China for use with colorectal cancer patients.
Recent data published in Clinical Cancer Research showed that Signatera can be used to stratify colorectal cancer patients based on growth or stability of their circulating tumor DNA levels over time, and the firm has previously validated the approach for early detection and prediction of impending cancer recurrence.
In 2020, the test also received Medicare coverage in the US for patients with stage II to stage III colon cancer.
Natera and BGI Genomics' partnership began when BGI saw the minimal residual disease test had been validated in the US and thought it would be beneficial to bring the technology to China for clinical practice, Shida Zhu, general manager of BGI Oncology, said. In June of this year, Signatera first became available to biopharmaceutical customers and clinicians in China under the brand name Hua Jian Wei.
Zhu said the firm waited to begin the clinical program until BGI had local production and delivery facilities available in China to perform the testing. It took two years to finish the facilities, he added, and Natera provided samples from its US-based production facilities to ensure the Chinese facilities were producing comparable results. Natera declined to comment on the partnership.
SEND INQUIRY
Please fill in fully your information to send email
CATEGORY
Agriculture